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Mastocytosis is a rare neoplastic disease characterized by a pathologic accumulation of tissue 
mast cells (MCs). Mastocytosis is often associated with a somatic point mutation in the Kit 
protooncogene leading to an Asp/Val substitution at position 816 in the kinase domain of 
this receptor. The contribution of this mutation to mastocytosis development remains 
unclear. In addition, the clinical heterogeneity presented by mastocytosis patients carrying 
the same mutation is unexplained. We report that a disease with striking similarities to 
human mastocytosis develops spontaneously in transgenic mice expressing the human 
Asp816Val mutant Kit protooncogene specifically in MCs. This disease is characterized by 
clinical signs ranging from a localized and indolent MC hyperplasia to an invasive MC tumor. 
In addition, bone marrow–derived MCs from transgenic animals can be maintained in culture 
for 
 

 
24 mo and acquire growth factor independency for proliferation. These results 
demonstrate a causal link in vivo between the Asp816Val Kit mutation and MC neoplasia and 
suggest a basis for the clinical heterogeneity of human mastocytosis.
 
Kit was originally identified as the viral onco-
gene (
 
v-kit
 
) responsible for the transforming
activity of the Hardy-Zuckerman IV feline
sarcoma virus (1). The Kit receptor, which
binds mouse Kit ligand (Kitl; stem cell factor
[SCF]), is a type III tyrosine kinase receptor
belonging to the platelet-derived growth factor
and macrophage colony-stimulating factor–1
receptors subfamily. This subfamily is character-
ized by the presence of five Ig-like domains in
the extracellular region and by a cytoplasmic ki-
nase domain split into an adenosine triphos-
phate–binding region and a phosphotransferase
region separated by an insert of variable length
(2). Kit and Kitl, which are encoded by the
murine dominant 
 
White spotting
 
 (
 
W
 
) and 
 
Steel
 
(
 
Sl
 
) loci, respectively, play major roles in he-
matopoiesis and in the generation of at least four
cell lineages: melanocytes, primordial germ cells,
interstitial cells of Cajal, and mast cells (MCs) (3).
Human mastocytosis, first described in
1869 (4), constitutes a heterogeneous group of
disorders characterized by the abnormal growth
and accumulation of MCs in diverse tissues.
Most cases begin in childhood and are benign
and confined to the skin (cutaneous mastocytosis,
the most frequent form being 
 
urticaria pigmentosa
 
).
In contrast, systemic mastocytosis (SM) is char-
acterized by the accumulation of neoplastic
MCs in multiple organs and can exhibit either
an indolent or an aggressive clinical course (5,
6). The organs most frequently affected are bone
marrow, skin, liver, spleen, and the gastrointesti-
nal tract (5, 6). Mastocytosis is often associated
with somatic mutations in the Kit protoonco-
gene, which cause its ligand-independent con-
stitutive phosphorylation and activation (7–9).
By far, the most frequent Kit mutation in masto-
cytosis patients is the Asp816Val substitution
(7–9). This mutation has also been reported in
other human cancers (10–12) and in several
leukemic MC lines (13–15). Despite the fre-
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quent presence of this activating Asp816Val Kit mutation in
mastocytosis patients, its specific contribution to MC patho-
genesis and tumor development remains unclear. Indeed, the
same mutation has been reported in several forms of the dis-
ease, ranging from mild skin MC hyperplasia to severe MC
leukemia (7, 16, 17). How could such a heterogeneous clin-
ical outcome be associated with a single mutation? Several
hypotheses can be proposed. First, the activating Asp816Val
Kit mutation may contribute to MC hyperplasia, but genetic
polymorphisms could influence the clinical outcome. In this
context, it is interesting to note that a polymorphism in the
IL-4R 
 

 
 chain gene has been recently associated with indo-
lent skin mastocytosis (18). Second, the timing of appearance
of the somatic mutation with respect to MC ontogeny (bone
marrow hematopoietic progenitor vs. more committed MC
precursor) could be critical in determining the severity of the
disease (19). Finally, the Asp816Val mutation could be seen
as a “permissive” mutation for MC transformation, but addi-
tional “hits” would be required to completely transform the
cell. The number and nature of these additional hits may also
determine the severity of the disease (20).
To decide between these various hypotheses, we have
generated transgenic mice expressing the human D816VKit
transgene in MCs. The development of spontaneous mas-
tocytosis in these mice demonstrates a direct role for
Asp816Val mutant Kit in the development of MC neoplasia.
In addition, the high variability of clinical signs observed in
inbred animals derived from the same transgenic line sug-
gests a basis for the clinical heterogeneity of mastocytosis.
 
RESULTS AND DISCUSSION
Asp816Val Kit mutant is causally associated with 
mastocytosis development
 
To directly evaluate whether the Asp816Val Kit mutation is
causally linked to mastocytosis development in vivo, we have
generated transgenic mice harboring a fusion transgene con-
sisting of the 571 bp primate chymase gene (
 

 
571-bchm)
promoter fragment and the human Kit protooncogene
cDNA with the codon 816 Asp
 
→
 
Val substitution (Fig. S1,
available at http://www.jem.org/cgi/content/full/jem.
20050807). The 
 

 
571-bchm promoter was used to direct
specific expression of the transgene to MCs, as previously de-
scribed by Liao et al. (21). Seven founders were identified by
Southern blot analysis on genomic DNA obtained from the
tail (Fig. S1). They appeared phenotypically normal and were
backcrossed onto the C57BL/6 strain to establish stable trans-
genic lines. Among these lines, four expressed the transgene-
specific transcripts in different tissues and in MCs and were
selected for subsequent experiments (Fig. S1).
Given the variable and nonspecific clinical manifestations
of mastocytosis, we killed transgenic and nontransgenic lit-
 
Table I.
 
Mastocytosis in Bchm/Asp816Val Kit transgenic mice
 
Age of mice
at analysis
Genotype
(# of mice)
MC pathology
None Hyperplasia Tumor
 

 
6 mo non-Tg
(
 
n
 
 
 

 
 16)
16 0 0
Bchm/D816VKit
(
 
n
 
 
 

 
 
 
29)
29 0 0
 

 
12 mo non-Tg
(
 
n
 
 
 

 
 22)
22 0 0
Bchm/D816VKit
(
 
n
 
 
 

 
 
 
28)
20 7 1
 
The frequency of MC disease is increased in the old (
 

 
12 mo) transgenic mice as 
compared to both old nontransgenic (non-Tg) littermates (P 
 
 
 
0.006 using the two-
tailed Fisher’s exact test) and young (
 

 
6 mo) transgenic mice (P 
 
 
 
0.002). MC disease 
is also more frequent (P 
 
 
 
0.02) in the entire transgenic group (
 
n
 
 
 
 
 
57) as compared 
with nontransgenic controls (
 
n
 
 
 

 
 38).
Figure 1. Histological studies of Bchm/Asp816Val Kit transgenic 
mice. Histopathological findings assessed by toluidine blue staining in four 
distinct transgenic mice. In the spleen of transgenic mice, MCs formed 
aggregates (B), whereas very few scattered MCs are seen (arrow) in non-
transgenic controls (A). Skin involvement is characterized by a striking 
increase of MCs (D) compared with nontransgenic littermates (C, arrows). 
(E) Accumulation of MCs in lymph node. A large MC tumor (F) infiltrating 
the mucosae was detected in the intestine of a transgenic mouse, 
which also presented with multiple MC foci in the liver (G, arrows). 
(H) Observation of extracellular granules in the vicinity of MCs. Magnifi-
cations: (A, B, E, F, and G) 200; (C and D) 320; (H) 1,000.
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termates from each expressing line at different ages to evalu-
ate the histopathological changes associated with Asp816Val
Kit expression. None of the nontransgenic mice and none of
the young (4–6 mo) transgenic animals showed any signs
of MC pathology (Table I). In addition, the percentages
of peritoneal MCs were similar in 4–9-mo-old nontrans-
genic (mean 
 

 
 SD 
 

 
 2.87 
 

 
 1.23%; 
 
n 
 

 
 13) and transgenic
(mean 
 

 
 SD 
 

 
 2.95 
 

 
 1.04%; 
 
n 
 

 
 10) animals. An abnor-
mal accumulation of MCs was noted in 8 out of 28 (28.6%)
old (12–18 mo) transgenic animals in the four lines studied.
Two of these mice exhibited isolated skin involvement (Fig.
1, C and D; Fig. 2 B; and Table II). Similar to SM patients,
the other six mice presented with MC aggregates involving
different tissues, and all but one presented an indolent disease
(Table II). These diseased animals therefore fulfilled the
World Health Organization criteria for human SM (5, 6).
The spleen, which has been reported as a primary site of MC
disease in SM (22), was the most frequently affected tissue
(Fig. 2 A). Affected spleens exhibited multiple randomly dis-
tributed foci of 5–30 MCs, with large MC aggregates pre-
dominating in the subcapsular area (Fig. 1, A and B). In one
animal, a striking increase of MCs was also detected in the
subcapsular sinus of a lymph node, showing morphological
features comparable to those described in the spleen (Fig. 1
E). Moderate increase in MC density in the heart or in the
stomach, not fulfilling the criteria for SM, was also detected
in three additional transgenic mice (Fig. 2, C and D). Of in-
terest, extracellular granules were observed in the vicinity of
MCs in some skin and gastrointestinal tract lesions, suggest-
ing that these cells were actively degranulating (Fig. 1 H).
No bone marrow involvement was noted, which was con-
sistent with the lack of transgene expression in this tissue
(Fig. S1). This likely results from the use of the chymase
promoter, which specifically targets differentiated MCs ex-
pressing mouse MC protease 5 (21).
In addition to this abnormal, but clinically silent, accu-
mulation of MCs, a large tumor (10 mm in diameter) was
detected in the intestine of an 18-mo-old transgenic mouse
(Fig. 1 F). Microscopically, it consisted of MCs, which ap-
peared enlarged and showed abundant basophilic granular
 
Table II.
 
Pathological abnormalities observed in 
Bchm/Asp816Val Kit transgenic mice
 
Animal
Transgenic
line Sex/age (mo)
MC
disorder
Affected 
tissues
 
23369 2 M/12 Hyperplasia Skin
23370 2 M/12 SM
 
a
 
Heart, spleen
23161 2 F/18 SM, tumor Intestine, spleen,
liver
23034 8 M/13 SM Spleen
23342 8 M/12 SM Lymph node
23039 11 M/13 SM Esophagus/stomach,
spleen
23044 16 F/13 Hyperplasia Skin
23356 16 F/12 SM Spleen, skin
 
a
 
According to the recent World Health Organization criteria applicable to human SM 
(references 5, 6).
Figure 2. Increased number of tissular MCs in Bchm/Asp816Val Kit 
transgenic mice. Paraffin-embedded sections of spleen (A), skin (B), stomach 
(C), and heart (D) from old (12 mo) transgenic (n  28) and nontrans-
genic (n  22) littermates were stained with toluidine blue. MCs were 
counted in 13–40 randomly chosen microscopic fields by a researcher 
unaware of the genotype of the mice. The horizontal bar represents the 
mean MC density in each group. Values indicate 3 SD for the control 
group. The number of splenic MCs is significantly increased in the trans-
genic mice as compared with nontransgenic littermates (P  0.018 using 
the two-tailed Mann-Whitney U test). In addition, nine transgenic mice, 
but none of the control mice, have increased density of MCs in the skin, 
stomach and/or heart (P  0.003 using the two-tailed Fisher’s exact test).
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cytoplasm and excentric, slightly atypical nuclei. These neo-
plastic MCs were strongly positive for toluidine blue stain,
which revealed numerous metachromatic cytoplasmic gran-
ules, some of a remarkably large size. This mouse also exhib-
ited multiple microscopic foci of MCs in the spleen and the
liver (Fig. 1 G), two organs that are often affected in human
SM (5, 6).
 
Asp816Val Kit mutant confers growth factor independency 
to bone marrow–derived MCs (BMMCs) from transgenic mice
 
To further analyze the impact of the Asp816Val Kit muta-
tion on MC proliferation, we produced BMMCs from
transgenic and nontransgenic littermates. As expected, only
BMMCs from transgenic animals expressed the transgene (Fig.
S1). Interestingly, we were repeatedly able to maintain trans-
genic, but not nontransgenic, BMMCs in continuous cul-
ture for 
 

 
24 mo. Furthermore, after several months in cul-
ture, transgenic BMMCs became independent of growth
factors and displayed equivalent proliferation rates with or
without Kitl (SCF) or IL-3 (Fig. 3 B). However, exogenous
IL-3 was still required during the initial phases of the culture
of transgenic BMMCs, suggesting that the expression of
Asp816Val Kit is necessary, but not sufficient, to confer
factor-independent proliferation. Sommer et al. (23) re-
cently reported similar findings for BMMCs derived from
KitV558
 

 
/
 

 
 mutant mice. This observation correlated well
with the fact that transgenic BMMCs exhibited a constitu-
tive phosphorylation of Kit (Fig. 3 A), which was noted
even before the acquisition of IL-3 independence (unpub-
lished data). The characteristic phosphorylated mature (145
Figure 3. Growth factor–independent Kit phosphorylation and 
proliferation of BMMCs from transgenic mice. (A) Total proteins from 
Asp816Val Kit and nontransgenic BMMCs, TF-1 cells, and Asp816Val Kit–
transfected BaF/3 and TF-1 cells were resolved by SDS-PAGE and probed 
with an antiphosphotyrosine antibody (top) and with an anti-Grb2 anti-
body (bottom) to assess the amount of protein loaded. (B) Proliferation of 
Asp816Val Kit and nontransgenic BMMCs assessed by [3H]thymidine 
incorporation. Data are expressed as means  SD of triplicate cultures. 
(C) Effect of increasing concentrations of tyrosine kinase inhibitors on the 
spontaneous proliferation of transgenic BMMCs and on growth factor–
induced proliferation of nontransgenic BMMCs. Results are shown as 
percentages of the proliferation obtained without addition of drugs. Data 
are expressed as means  SD of triplicate samples. (D) Kit phosphorylation 
in BMMC lysate from transgenic mice treated or not with the indicated 
tyrosine kinase inhibitors.
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kD) and immature (125 kD) forms of Kit detected in trans-
genic BMMCs were similar to those observed in transfected
BaF/3 or TF-1 cells expressing the human Asp816Val Kit
mutant receptor (Fig. 3 A). This phosphorylation of Kit in
transgenic BMMCs was associated with intense and con-
stitutive activation of STAT3 but not of ERK1,2 or AKT
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20050807/DC1), a pattern that was not observed in
Kitl-stimulated nontransgenic BMMCs. This altered signal
transduction pattern suggests that STAT3 plays an important
role in Asp816Val Kit–induced MC transformation.
The ability to generate long-lived BMMCs expressing
the mutant receptor prompted us to assess their in vitro sen-
sitivity to a range of tyrosine kinase inhibitors. STI571 effi-
ciently inhibits wild-type but not Asp816Val Kit (24). In line
with these data, we observed that STI571 inhibited the Kitl-
induced proliferation of nontransgenic BMMCs with a cel-
lular IC
 
50
 
 of 300 nM, whereas factor-independent transgenic
BMMCs were considerably more resistant (Fig. 3 C). In
sharp contrast, transgenic and Kitl-stimulated nontransgenic
BMMCs displayed identical sensitivity to PP2 (Fig. 3 C), a
kinase inhibitor active on both wild-type and Asp816Val Kit
(not depicted) (25). The inactive analogue PP3 had no im-
portant effect, nor did PP2 and STI571 inhibit IL-3–induced
proliferation of nontransgenic BMMCs (Fig. 3 C). Collec-
tively, these data strongly suggest that the factor-indepen-
dent proliferation of the transgenic BMMCs is the conse-
quence of the expression of the mutant Kit. This was further
supported by the fact that inhibition of transgenic BMMC
proliferation correlated closely with the inhibition of Kit au-
tophosphorylation (Fig. 3 D).
 
Clues on the pathogenesis and clinical heterogeneity of 
human mastocytosis
 
Our finding that the expression of Asp816Val human Kit in
MCs can recapitulate essential features of mastocytosis in
mice is direct proof that this mutation plays an essential role
in the abnormal accumulation and/or growth of MCs char-
acteristic of this disease. Moreover, this transforming event
can occur late in MC differentiation, an observation that
correlates well with the fact that patients suffering from in-
dolent SM can harbor the mutation without bone marrow
involvement (26). Interestingly, mice originating from the
same transgenic line (Table II) can develop all clinical forms
of the human disease (MC hyperplasia selectively affecting
the skin, SM, or MC tumor) while sharing the same site of
transgene integration, timing of expression of the gain-of-
function Kit mutation, genetic background, and environ-
mental influences. This result therefore suggests that the ex-
pression of Asp816Val Kit is necessary for the neoplastic
transformation of MCs but that transformation requires the
involvement of additional somatic mutations. This hypothe-
sis is strengthened by the fact that even though this mutation
confers oncogenic properties in growth factor–dependent
cell lines (27–29), it is unable to transform primary hemato-
poietic cells (30). In the same line of evidence, two other
transgenic mice expressing different constitutively active mu-
rine Kit mutants, in particular the Val558del mutant that is
sufficient to cause gastrointestinal stromal tumors, did not
develop sign of mastocytosis, except for a mild increase in
skin MCs (23, 29).
Collectively, our results are in agreement with the Knud-
son model (20), which proposes that cancer is rarely associ-
ated with a single mutation but has to be seen as a multistep
process in which each step correlates with one or more dis-
tinct mutations in major regulatory genes. The nature, the
accumulation, and/or the timing of appearance of these ad-
ditional events would be crucial in determining the clinical
outcome of the disease. Our transgenic mouse model offers a
new tool to investigate in vivo the molecular requirements
for the progression of mastocytosis. Moreover, it provides
both a cellular and an animal model for preclinical testing of
protein tyrosine kinase inhibitors potentially useful for pa-
tients with SM.
 
MATERIALS AND METHODS
 
Transgene construction.
 
Site-directed mutagenesis was performed on
the human Kit cDNA encoding the isoform lacking the GNNK sequence
and containing Ser 715, to replace the aspartic acid at position 816 by a va-
line. The mutant Kit cDNA was cloned into a pBluescript vector that con-
tained the SV40 late polyA region. A 571 bp fragment of the 5
 
	
 
 flanking se-
quences of the baboon chymase promoter (
 

 
571-bchm; a gift from A.
Husain, Victor Chang Cardiac Research Institute, Sydney, Australia) (21)
was cloned upstream of the mutated human Kit cDNA.
 
Generation of Bchm/Asp816Val Kit transgenic mice.
 
Transgenic
mice were generated by pronuclear injection of the linear Bchm/Asp816Val
Kit transgene into fertilized (C57BL/6 
 


 
 DBA2) F2 zygotes. Founder ani-
mals were identified by Southern blot analysis (Fig. S1). The French Minis-
try of Research approved these genetically modified animal studies. All ani-
mal studies were performed in accordance with the European Union
guidelines and had local committee approval. Mice were backcrossed up to
nine times on the C57BL/6 genetic background.
 
RT-PCR analysis.
 
To assess transgene expression, 3 
 

 
g of total RNA
was treated with RNase-free DNase (Roche) transcribed with Superscript
(Invitrogen), using Oligo dT as a primer, and amplified in a 40-cycle PCR
using the transgene-specific oligonucleotides 5
 
	
 
-CCGCTTCCTCCTC-
CCAGCCTC-3
 
	
 
 and 5
 
	
 
-GTTTCAGGTTCAGGGGGAGGTGTG-3
 
	
 
.
Primers used for 
 

 
-actin cDNA amplification were 5
 
	
 
-CCATCGTGGGC-
CGCCCTAGGCAC-3
 
	
 
 and 5
 
	
 
-CCGGCCAGCCAGGTCCAGAC-3
 
	
 
.
 
Tissue preparation and histological analysis.
 
Mice were killed, and
multiple tissues (skin, spleen, liver, lymph nodes, femur, stomach, jejunum,
ileum, colon, lung, heart, brain, kidney, and genitals) were dissected, fixed
in formalin for 24 h, and embedded in paraffin. 5 
 

 
m–thick tissue sections
were stained by hematoxylin and eosin or periodic acid Schiff. Acid tolui-
dine (0.5% toluidine blue in 0.5 M HCl) staining was performed to identify
MCs. Tissue MCs were enumerated in 13–40 independent microscopic
fields from 3–4 toluidine blue–stained sections for each mouse.
 
Culture of BMMCs.
 
BMMCs were derived from femurs of 2-mo-old
male mice. Bone marrow cells were cultured at a starting density of 2 
 


 
 10
 
5
 
cells/ml in Optimem medium supplemented with 
 
L
 
-glutamine, penicillin,
streptomycin, 10% fetal calf serum (Invitrogen), and 2 ng/ml murine re-
combinant IL-3 (Immugenex). The medium was renewed every 5–7 d.
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Cells were used after their differentiation into MCs, which occurred after at
least 28 d in culture. At monthly intervals, BMMCs were deprived of IL-3
to assess the acquisition of growth-factor independency.
 
Proliferation assays.
 
BMMCs were washed twice in PBS, plated in trip-
licates at 5 
 


 
 10
 
4
 
 cells/well in 96-well plates, and stimulated with either 250
ng/ml Kitl (SCF), 10 ng/ml IL-3, or without added growth factors. After
2 d of culture, 1 
 

 
Ci [
 
3
 
H]thymidine was added for 6 h. For the inhibition
of BMMC proliferation, the drugs were added at the beginning of the cul-
ture at the concentrations indicated in the figures. STI571 was provided by
E. Buchdunger (Novartis Pharma); PP2 and PP3 were purchased from Cal-
biochem-Novabiochem.
 
Western blotting analysis.
 
For each assay, 5 
 


 
 10
 
6
 
 cells were lysed, and
the equivalent of 5 
 


 
 105 cell lysate was loaded per assay, run on a 7.5%
SDS-PAGE gel, and transferred to a nylon membrane. Anti-PS476-AKT,
anti-PY705-STAT3, and anti-STAT3 (Cell Signaling Technology), 4G10
antiphosphotyrosine (UBI), anti-active-(pTEpY)ERK1,2, and anti-Grb2
antibodies (Santa Cruz Biotechnology, Inc.) were used in immunoblotting
according to the manufacturers’ instructions. Membranes were incubated
either with horseradish peroxidase–conjugated goat anti–mouse or anti–rab-
bit IgG antibodies (Immunotech). HRP revelation was performed by incu-
bation with ECL reagent (GE Healthcare). For drug-induced inhibition of
Kit phosphorylation, Asp816Val Kit BMMCs were serum-starved for 3 h
and treated with or without tyrosine kinase inhibitors for an additional 90
min before cell lysis. Membranes were blotted with the 4G10 anti-phos-
photyrosine antibody.
Online supplemental material. Fig. S1 contains detailed information
about the construct and shows transgene integration in founder mice DNA
and its expression in established transgenic lines. Fig. S2 characterizes the
downstream signaling pathways induced by Asp816Val Kit receptor and
likely implicated in MC transformation. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050807/DC1.
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